We propose that the tissue-specific interplay between ncRNAs might partly explain the different sensitivity to BRAF inhibitors in colon adenocarcinoma and melanoma harboring the same oncogenic mutation in BRAF (Figure 4). Here, BRAF is linked to melanoma.